Adipocytokines and the risk of ischemic stroke: The PRIME Study

Annals of Neurology

Volumn 71, Issue 4, 2012, Pages 478-486

  Prugger, Christof ^a   Luc, Gérald ^b   Haas, Bernadette ^c   Arveiler, Dominique ^c   MacHez, Emeline ^b   Ferrieres, Jean ^d   Ruidavets, Jean Bernard ^d   Bingham, Annie ^a   Montaye, Michèle ^b   Amouyel, Philippe ^b   Yarnell, John ^e   Kee, Frank ^e   Ducimetiere, Pierre ^f   Empana, Jean Philippe ^a  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPSIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; RESISTIN;

ADULT; ARTICLE; BODY MASS; BRAIN ISCHEMIA; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADIPOKINES; CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; STROKE;

EID: 84860197535     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22669     Document Type: Article

References (41)

1. Bogers RP, Bemelmans WJ, Hoogenveen RT, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med 2007; 167: 1720-1728.
2. Strazzullo P, D'Elia L, Cairella G, et al. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke 2010; 41: e418-e426.
3. Fain JN, Buehrer B, Bahouth SW, et al. Comparison of messenger RNA distribution for 60 proteins in fat cells vs the nonfat cells of human omental adipose tissue. Metabolism 2008; 57: 1005-1015.
4. Sattar N, Wannamethee G, Sarwar N, et al. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol 2009; 53: 167-175.
5. Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006; 114: 623-629.
6. Pischon T, Bamberger CM, Kratzsch J, et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005; 13: 1764-1771.
7. Luc G, Empana JP, Morange P, et al. Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study. Int J Obes 2010; 34: 118-126.
8. Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010; 121: 2388-2397.
9. Dekker JM, Funahashi T, Nijpels G, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008; 93: 1489-1496.
10. Matsumoto M, Ishikawa S, Kajii E,. Association of adiponectin with cerebrovascular disease: a nested case-control study. Stroke 2008; 39: 323-328.
11. Stott DJ, Welsh P, Rumley A, et al. Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol 2009; 38: 253-261.
12. Weikert C, Westphal S, Berger K, et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008; 93: 2647-2653.
13. Soderberg S, Ahren B, Stegmayr B, et al. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke 1999; 30: 328-337.
14. Rajpathak SN, Kaplan RC, Wassertheil-Smoller S, et al. Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the Women's Health Initiative. Stroke 2011; 42: 1813-1820.
15. Yarnell JW,. The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland. Prospective Epidemiological Study of Myocardial Infarction. QJM 1998; 91: 667-676.
16. Canoui-Poitrine F, Luc G, Bard JM, et al. Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study. Cerebrovasc Dis 2010; 30: 252-259.
17. Canouï-Poitrine F, Luc G, Mallat Z, et al. Systemic chemokine levels, coronary heart disease, and ischaemic stroke events: the PRIME Study. Neurology 2011; 77: 1165-1173.
18. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
19. Chambless LE, Heiss G, Shahar E, et al. Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2004; 160: 259-269.
20. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS,. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
21. Janes H, Pepe MS, Gu W,. Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 2008; 149: 751-760.
22. Kizer JR, Barzilay JI, Kuller LH, Gottdiener JS,. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab 2008; 93: 3357-3364.
23. Laughlin GA, Barrett-Connor E, May S, Langenberg C,. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007; 165: 164-174.
24. Wannamethee SG, Whincup PH, Lennon L, Sattar N,. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007; 167: 1510-1517.
25. Sattar N, Nelson SM,. Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox. J Clin Endocrinol Metab 2008; 93: 3299-3301.
26. Lee TS, Lin CY, Tsai JY, et al. Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages. Life Sci 2009; 84: 97-104.
27. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-740.
28. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI,. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 2010; 14: 1419-1431.
29. Calabro P, Cirillo P, Limongelli G, et al. Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-kB-dependent pathway. J Vasc Res 2011; 48: 59-66.
30. Hopkins TA, Ouchi N, Shibata R, Walsh K,. Adiponectin actions in the cardiovascular system. Cardiovasc Res 2007; 74: 11-18.
31. Choy LN, Rosen BS, Spiegelman BM,. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992; 267: 12736-12741.
32. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-2639.
33. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-2116.
34. Weikert C, Westphal S, Luley C, et al. Within-subject variation of plasma resistin levels over a 1-year period. Clin Chem Lab Med 2007; 45: 899-902.
35. Pischon T, Hotamisligil GS, Rimm EB,. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 2003; 49: 650-652.
36. Tsukahara T, Nakashima E, Watarai A, et al. Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2009; 84: 179-186.
37. Ichida Y, Hasegawa G, Fukui M, et al. Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes. Pharmacology 2006; 76: 34-39.
38. Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, et al. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 311-316.
39. Seto SW, Lam TY, Or PM, et al. Folic acid consumption reduces resistin level and restores blunted acetylcholine-induced aortic relaxation in obese/diabetic mice. J Nutr Biochem 2010; 21: 872-880.
40. Ogorodnikova AD, Wassertheil-Smoller S, Mancuso P, et al. High-molecular-weight adiponectin and incident ischemic stroke in postmenopausal women: a Women's Health Initiative Study. Stroke 2010; 41: 1376-1381.
41. Wang TJ,. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011; 123: 551-565.